Replies to post #202230 on Biotech Values

[DewDiligence]

Questioning RGLS’ motives:

As time goes by, I'm not sure if this reflects worse on $RGLS management or their other assets https://t.co/peYELEZLS0

— Andrew G. (@BioDueDiligence) June 27, 2016

[DewDiligence]

RGLS has a lot of work to do to lift the FDA clinical hold on RG-101, as detailed on today’s CC. They make it all sound easy, but I don’t think it actually is.